Pyxis Oncology (PYXS) Non Operating Investment Income (2023 - 2026)
Pyxis Oncology (PYXS) posted quarterly Non Operating Investment Income of -$16000.0 for Q4 2025, up 91.16% year-over-year from -$8369.9 in Q4 2024, and down 121.62% quarter-over-quarter from $74000.0 in Q3 2025.
Pyxis Oncology (PYXS) Non Operating Investment Income (2023 - 2026) Analysis & Trends
Pyxis Oncology (PYXS) has reported Non Operating Investment Income for 3 consecutive years, with -$16000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Non Operating Investment Income rose 91.16% year-over-year to -$16000.0; the TTM figure through Dec 2025 stood at -$117000.0 (down 209.35% YoY), while the FY2025 annual figure was -$117000.0, down 209.35% from the prior year.
- Non Operating Investment Income retreated to -$16000.0 in Q4 2025 per PYXS's latest filing, from $74000.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $696000.0 in Q1 2023 and bottomed at -$781000.0 in Q2 2023.
- Historically, Non Operating Investment Income has averaged $4416.7 across 3 years, with a median of -$31000.0 in 2023.
- On a YoY basis, Non Operating Investment Income climbed as much as 2365.0% in 2024 and fell as far as 207.74% in 2024.
- Pyxis Oncology's Non Operating Investment Income stood at $168000.0 in 2023, then plunged by 207.74% to -$181000.0 in 2024, then surged by 91.16% to -$16000.0 in 2025.
- Business Quant data shows PYXS's Non Operating Investment Income at -$16000.0 in Q4 2025, $74000.0 in Q3 2025, and -$54000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Pyxis Oncology | 198.37 Mn | 165.38 Mn | - | -4,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4,000.00 |
| Jun 30, 2026 | -4,000.00 |
| Dec 31, 2025 | -16,000.00 |
| Dec 31, 2025 | -16,000.00 |
| Sep 30, 2025 | 74,000.00 |
| Sep 30, 2025 | 74,000.00 |
| Jun 30, 2025 | -54,000.00 |
| Jun 30, 2025 | -54,000.00 |
| Mar 31, 2025 | -121,000.00 |
| Mar 31, 2025 | -121,000.00 |
| Dec 31, 2024 | -181,000.00 |
| Dec 31, 2024 | -181,000.00 |
| Sep 30, 2024 | 453,000.00 |
| Sep 30, 2024 | 453,000.00 |
| Jun 30, 2024 | -42,000.00 |
| Jun 30, 2024 | -42,000.00 |
| Mar 31, 2024 | -123,000.00 |
| Mar 31, 2024 | -123,000.00 |
| Dec 31, 2023 | 168,000.00 |
| Dec 31, 2023 | 168,000.00 |